An observational study in Heart Failure and Children, sponsored by Shanghai Jiao Tong University School of Medicine. Enrolling by invitation at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-04-15.
Sponsored by Shanghai Jiao Tong University School of Medicine · Observational
To establish a multicenter pediatric end-stage heart failure (ESHF) specialized disease data platform and promote its adoption across major children's medical centers nationwide. Based on this platform, conduct a national multicenter cohort study on specialized treatments for pediatric ESHF (including pharmacotherapy, ventricular assist devices, heart transplantation, etc.). This initiative will provide a foundational platform for advancing national clinical research on pediatric end-stage heart failure.
5,803 studies on the registry are indexed under Heart Failure; 1,222 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 1,719 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Shanghai Jiao Tong University School of Medicine is the lead sponsor of 370 studies on the registry; 107 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children with end-stage heart failure (ESHF) receiving care at multiple Chinese tertiary referral centers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet any of the following criteria despite receiving optimal guideline-directed medical therapy (GDMT):
Severe and persistent heart failure symptoms [New York Heart Association (NYHA) Class III (advanced) or IV];
Significant cardiac dysfunction, defined as:
Left ventricular ejection fraction ≤30%
Isolated right ventricular failure
Non-operable severe valvular or congenital abnormalities
Persistently elevated B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels
Severe diastolic dysfunction or left ventricular structural abnormalities (based on ESC definitions for heart failure with preserved ejection fraction [HFpEF] and heart failure with mildly reduced ejection fraction [HFmrEF]);
Requirement of:
High-dose intravenous diuretics (or combination diuretic therapy) for pulmonary/systemic congestion, OR
Inotropic/vasoactive agents for low cardiac output, OR
Management of malignant arrhythmias Resulting in >1 unplanned hospital visits or admissions within the past 12 months;
Severely impaired mobility due to cardiac causes with either:
Inability to ambulate, OR
6-minute walk distance \<300 m, OR
Peak oxygen consumption (PvO₂) \<12-14 mL/kg/min. -
Exclusion Criteria:
Concurrent life-limiting systemic disorders
Structural cardiac lesions with indication for surgical/interventional correction -
A prospective multicenter cohort study on pediatric end-stage heart failure (ESHF) in China focusing on multicenter, multidimensional comprehensive analysis of demographic characteristics, risk factors, treatment efficacy, etiologies, prognoses, complications
Composite of cardiovascular death, heart transplantation, LVAD implantation or WHF hospitalization
WHF hospitalization: The patient was hospitalized for worsening heart failure; LVAD: left ventricular assistant device
Time frame: From enrollment to the follow up at 1 year, 3 years, 5 years
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Nov 2026, 35 months after the start.
Of 665 non-industry observational studies under Heart Failure, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 89. This study's planned 35 months is below that.
Counting every sponsor, half of 825 studies reached it within 40 months; a quarter within 21 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University School of Medicine →